Comparison of topical fixed-combination fortified vancomycin-amikacin (VA solution) to conventional separate therapy in the treatment of bacterial corneal ulcer

Eye

Volumn 23, Issue 2, 2009, Pages 294-298

  Chiang, C C ^a,b   Lin, J M ^a   Chen, W L ^a   Chiu, Y T ^a   Tsai, Y Y ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Amikacin; Bacterial keratitis; Fortified antibiotics; Vancomycin

Indexed keywords

AMIKACIN; AMIKACIN PLUS VANCOMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; DRUG COMBINATION; EYE DROPS;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CORNEA ULCER; DRUG EFFICACY; DRUG POTENCY; EPITHELIZATION; FEMALE; HEALING; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL RECORD REVIEW; MONOTHERAPY; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SCHOOL CHILD; TIME SERIES ANALYSIS; CORNEAL ULCER; DRUG COMBINATION; EYE INFECTIONS, BACTERIAL; MEDICINAL CHEMISTRY; MICROBIOLOGY; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CHILD; CORNEAL ULCER; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 60149107495     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6703078     Document Type: Article

References (21)

1. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol 1991; 112(4 Suppl): 34S-47S.
2. Parks DJ, Abrams DA, Sarfarazi FA, Katz HR. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. Am J Ophthalmol 1993; 115: 471-477.
3. Callegan MC, Engel LS, Hill JM, O'Callaghan RJ. Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis. Invest Ophthalmol Vis Sci 1994; 35: 1033-1037.
4. Guzek JP, Chacko D, Kettering JD, Wessels IF, Aprecio RM. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis. Cornea 1994; 13: 500-524.
5. Lauffenburger MD, Cohen KL. Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococus and Pseudomonas keratitis. Cornea 1993; 12: 517-521.
6. Bower KS, Kowalski RP, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol 1996; 121: 712-715.
7. Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003; 136: 500-505.
8. Wilhelmus KR, Abshire RL, Schlech BA. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol 2003; 121: 1229-1233.
9. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 1999; 106: 1313-1318.
10. Aliprandis E, Ciralsky J, Lai H, Herling I, Katz HR. Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits. Cornea 2005; 24: 201-205.
11. Lin JM, Tsai YY, Fu YL. The fixed combination of fortified vancomycin and amikacin ophthalmic solution - VA solution: in vitro study of the potency and stability. Cornea 2005; 24: 717-721.
12. Rexed U. The pH of the lachrymal fluid determined by a capillary micro-glass electrode. Acta Ophthalmol 1958; 36: 711-718.
13. Fechner PU, Teichmann KD. Ocular Therapeutics: Pharmacology and Clinical Application. Thorofare, NJ: Slack Inc., 1998.
14. Fong CF, Hu FR, Tseng CH, Wang IJ, Chen WL, Hou YC. Antibiotic susceptibility of bacterial isolates from bacterial keratitis cases in a university hospital in Taiwan. Am J Ophthalmol 2007; 144(5): 682-689.
15. Bourcier T, Thomas F, Borderie V, Chaumeil C, Laroche L. Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol 2003; 87(7): 834-838.
16. Bu P, Riske PS, Zaya NE, Carey R, Bouchard CS. A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. J Ocul Pharmacol Ther 2007; 23(3): 213-220.
17. Yu VL, Rhame FS, Pesanti EL, Axline SG. Amikacin therapy. Use against infections caused by gentamicin- and tobramycin-resistant organisms. JAMA 1977; 238: 943-947.
18. Bharathi MJ, Ramakrishnan R, Vasu S, Meenakshi R, Palaniappan R. In-vitro efficacy of antibacterials against bacterial isolates from corneal ulcers. Indian J Ophthalmol 2002; 50(2): 109-114.
19. Sharma S, Kunimoto DY, Garg P, Rao GN. Trends in antibiotic resistance of corneal pathogens: part I. An analysis of commonly used ocular antibiotics. Indian J Ophthalmol 1999; 47: 95-100.
20. Ventura MP, Saheb NE, Solari HP, Saraiva VS, Vianna RN, Burnier Jr MN. Cost considerations of the new fixed combinations for glaucoma medical therapy. J Clin Pharm Ther 2005; 30: 251-254.
21. Zimmerman TJ, Zalta AH. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol 1983; 28: 252-258.